Clostridioides Difficile Infection (CDI) in children (<18 years of age) |
Publication: 08/09/2016 |
Next review: 21/01/2024 |
Clinical Guideline |
CURRENT |
ID: 4731 |
Approved By: Improving Antimicrobial Prescribing Group |
Copyright© Leeds Teaching Hospitals NHS Trust 2021 |
This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated. |
Clostridioides Difficile Infection (CDI) in children (<18 years of age)
Click here to view the adult guideline (>18 years of age)
Diagnostics
Symptoms or clinical signs cannot be used to reliably distinguish CDI from other causes of diarrhoea in children.
CDI diagnosis requires either laboratory confirmation or visualization of pseudomembranes on sigmoidoscopy or colonoscopy. [Evidence level B]
It is not recommended to conduct routine testing for CDI in children younger than 2 years (carrier state rate or gut colonisation is highest in this age group) and consider other causes of diarrhoea, particularly viruses.
For patients with a presumed diagnosis of CDI the following diagnostic tests should be taken to confirm diagnosis:
All patients (≥2 years) with symptoms of diarrhoea (type 5-7 on Bristol Stool Chart) and no clear alternative cause should have a stool sample sent marked for C. difficile testing. |
All patients should have: FBC, CRP and U&E’s |
Patients who were initially excluded clinically, but still have persistent symptoms (>48 hours) of diarrhoea (type 5-7 on Bristol Stool Chart) after action taken to correct diarrhoea, should have a stool sample sent marked for C. difficile testing. |
In suspected cases of ‘silent’ CDI, such as ileus, toxic megacolon or pseudomembranous colitis without diarrhoea, request abdominal imaging e.g. abdominal x-ray, CT scanning or abdominal US. |
Patients with severe infection should have serum lactate measured on a daily basis until clinical signs of improvement or surgical intervention is required. |
Please see Clostridioides difficile (previously known as Clostridium difficile); Guideline for the prevention of transmission in adults and children >2 years with Clostridioides difficile Infection (CDI) for further information about investigations, diagnosis and source isolation.
Severity assessment
Patients with a confirmed CDI should be assessed daily for severity of infection including signs and symptoms of colitis.
Severity assessment of Clostridiodes difficile infection in children | |
Total score: |
|
Criteria |
Points |
Diarrhoea >5 times a day |
1 |
Abdominal pain and discomfort |
1 |
Rising white cell count |
1 |
Raised C-reactive protein (CRP) |
1 |
Pyrexia >38° |
1 |
Evidence of pseudomembranous colitis |
2 |
Intensive care unit requirement |
2 |
Empirical treatment
Any concurrent antibiotics should be stopped wherever possible or substituted for an agent with lower risk of inducing CDI if an underlying infection still requires treatment.
If a patient is taking a Proton-pump inhibitor (PPI) this should be reviewed and stopped where possible.
Empirical options for CDI | |||
Severity |
Recommended treatment |
Notes |
Duration |
Mild severity |
If symptoms are settling by time of CDI confirmation there is no need to treat. It treatment is felt appropriate follow the regimen for moderate severity. |
||
Moderate severity |
1st Line Option3 Enteral Vancomycin
2nd Line or if Vancomycin unsuitable Oral Metronidazole
|
For patients who are nil by mouth, Metronidazole Formulations available for Vancomycin
Formulations available for Metronidazole
|
10 days |
Severe |
Enteral Vancomycin2:
Formulations: AND
|
Surgical review may be indicated if evidence of caecal dilatation on imaging. |
Review at 10 days |
Recurrent CDI and treatment failure
Recurrence of CDI is usually defined as recurrence of diarrhoea (at least 3 consecutive type 5-7 stools) and a positive C. difficile toxin assay within 30 days of a previous CDI episode and after resolution of previous symptoms (i.e. no diarrhoea for at least 48 hours).
Treatment failure should not be assessed before day 7 of therapy.
Diarrhoea should resolve within 1-2 weeks, if diarrhoea has improved but persists at 14 days but the patient is otherwise stable, the WCC is normal, and there is no abdominal pain or distension, the persistent diarrhoea may be not due to infectious cause.
Do not retest C. difficile toxin positive cases if patients are still symptomatic within a period of 28 days unless symptoms resolve and then recur and there is a need to confirm recurrent CDI.
1st recurrence |
The regimens used to treat patients with first episodes of C difficile associated colitis can be repeated for the first recurrence. |
2nd or later recurrence |
Second or later recurrences should typically be treated with Vancomycin
|
Footnotes
- Doses taken from cBNF state for children aged 12-18 years. The age has been amended 12-16 years in this guideline to prevent confusion between adult and paediatric guidelines.
- Vancomycin oral liquid 50mg/ml prepared as extemp in dispensary. 7 day expiry -ensure adequate arrangements made for supply for discharge
- Data on the relative effectiveness (measured as treatment failure) of metronidazole compared to vancomycin is limited in children. IDSA/SHEA guidelines [McDonald, 2018] advise that for ‘mild’ disease, clinicians may choose either agent. However, the limited data does show a trend toward vancomycin being more effective, but this evidence can be considered weak quality, and is not statistically significant. Therefore, clinicians may choose either but should consider:
- availability and palatability of formulations
- dose and administration instructions
- allergy status
|
Provenance
Record: | 4731 |
Objective: | |
Clinical condition: | Clostridioides Difficile Infection (CDI) |
Target patient group: | Paediatric patients with Clostridioids difficile infection |
Target professional group(s): | Secondary Care Doctors Pharmacists |
Adapted from: |
Evidence base
Evidence Base
- NICE: Clostridioides difficile infection:antimicrobial prescribing NICE guideline [NG199] Published 23/07/21
- UKHSA: Clostridioides difficile: guidance, data and analysis. The characteristics, diagnosis, management, surveillance and epidemiology of Clostridioides difficile (C.difficile). Last updated 6/09/21
- NHS England Commissioning Criteria Policy Immunoglobulin 2021 (available electronically: https://www.england.nhs.uk/wp-content/uploads/2021/12/cpag-policy-for-therapeutic-immunoglobulin-2021-update.pdf)
- NICE Medical technologies guidance (MTG 71) – Faecal microbiota transplant for recurrent Clostridioides difficile infection. Aug 2022.
Approved By
Improving Antimicrobial Prescribing Group
Document history
LHP version 2.2
Related information
Not supplied
Equity and Diversity
The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.